Abstract:Background Pancreatic ductal adenocarcinoma (PDAC), the most common subtype of pancreatic cancer, is associated with poor prognosis. Previous publications have indicated tertiary lymphoid structure (TLSs) and CD8 + T-cells as prognostic indicators for PDAC, and a positive correlation between CD8 + T-cell infiltration and TLSs was also observed in PDAC. However, different states of TLSs infiltration occurs, and not all stages of TLSs maturation are correlated with a high abundance of CD8 + T-cells in the tumor microenvironment (TME), also CD8 + T-cell infiltration could be influenced by other factors, thus an integrative characterization of the TLSs and CD8 + T-cells is urgently needed. Herein, we aimed to establish a novel scoring system for evaluating the risk for PDAC based on TLSs- and CD8 + T-cells-related genes. Methods In this study, we analyzed single-cell sequence (scRNA-seq) data from PDAC patients in GSA: CRA001160 cohort, which indicated the positive relationship between TLSs presence and CD8 + T-cell infiltration. TCGA-PAAD was used as the training cohort. ICGC-CA, E-MTAB-6134, and the joint cohort of GSE71729 and GSE85916 were used for validation. Using bioinformatics and machine algorithms, we established and validated a scoring method (T-C score) based on survival related genes highly expressed in TLSs and CD8 + T-cells in PDAC, which was then used to stratify patients into the low- and high- T-C score groups. Following that, we analyzed the differences in survival, pathway enrichment, mutation status, immune cell infiltration, expression of immune checkpoint associated genes, tumor stemness, and response to anti-tumor therapy between the two groups. Results The overall survival differed significantly between the low- and high- T-C score groups throughout the training and validation cohort. Good accuracy of the T-C score in predicting 1-, 2-, 3-, 4-, and 5-year survival was further confirmed in the training and validation cohort, respectively. Furthermore, the low T-C score group was correlated with lower tumor mutation burden (TMB), and lower levels of tumor stemness, compared to the high T-C score group, Besides, analysis using the TIDE web tool has verified that patients with lower T-C score exhibited advantages in immunotherapeutic responses. Patients with lower T-C scores might be more sensitive to the chemotherapeutic regimen and multi-kinase inhibitors. Collectively, the T-C score based on the TLSs- and CD8 + T-cells-related gene signature could serve as an effective model for predicting the survival and therapeutic responses of PDAC patients.

A Single-Cell Atlas of Tumor-Infiltrating Immune Cells in Pancreatic Ductal Adenocarcinoma

A Single-Cell Atlas of Tumor-In FI Ltrating Immune Cells in Pancreatic Ductal Adenocarcinoma

Prognostic Value of Programmed Cell Death Protein 1 Expression on CD8+ T Lymphocytes in Pancreatic Cancer

High-dimensional Single-Cell Analysis Unveils Distinct Immune Signatures of Peripheral Blood in Patients with Pancreatic Ductal Adenocarcinoma

Single-cell Transcriptome Reveals the Heterogeneity of Malignant Ductal Cells and the Prognostic Value of REG4 and SPINK1 in Primary Pancreatic Ductal Adenocarcinoma

Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy

Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma

Immunological Classification of Pancreatic Carcinomas to Identify Immune Index and Provide a Strategy for Patient Stratification

Unique Spatial Immune Profiling in Pancreatic Ductal Adenocarcinoma with Enrichment of Exhausted and Senescent T Cells and Diffused CD47-SIRPα Expression

Additional File 29 of Proteogenomic Insights into the Biology and Treatment of Pancreatic Ductal Adenocarcinoma

Intra-tumoral Infiltration of Adipocyte Facilitates the Activation of Antitumor Immune Response in Pancreatic Ductal Adenocarcinoma

Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers

Immune Profiling and Prognostic Model of Pancreatic Cancer Using Quantitative Pathology and Single-Cell RNA Sequencing.

The PD-L1 Expression and Tumor-Infiltrating Immune Cells Predict an Unfavorable Prognosis in Pancreatic Ductal Adenocarcinoma and Adenosquamous Carcinoma.

PD-1+CD8+ T Cells Proximal to PD-L1+CD68+ Macrophages Are Associated with Poor Prognosis in Pancreatic Ductal Adenocarcinoma Patients

Identification of Key Prognostic Biomarker and Its Correlation with Immune Infiltrates in Pancreatic Ductal Adenocarcinoma

Multimodal Mapping of the Tumor and Peripheral Blood Immune Landscape in Human Pancreatic Cancer

In‐depth immune profiling of peripheral blood mononuclear cells in patients with pancreatic ductal adenocarcinoma reveals discriminative immune subpopulations

Pancreatic ductal adenocarcinoma cells reshape the immune microenvironment: Molecular mechanisms and therapeutic targets

Comprehensive Genomic Analysis of the Prognostic and Immunological Characteristics of Tertiary Lymphoid structures and CD8+ T-cells in Pancreatic Ductal Adenocarcinoma

The Crosstalk Between Malignant Cells and Tumor-Promoting Immune Cells Relevant to Immunotherapy in Pancreatic Ductal Adenocarcinoma